The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis

Follicular fluid hormonal profile and cumulus cell gene expression in controlled ovarian hyperstimulation with recombinant FSH: effects of recombinant LH administration

“…The study population consisted of ICSI patients with major indications for ART such as tubal infertility or unexplained infertility and/ or partners with semen abnormalities. Average patient age was 33 years (range [31][32][33][34][35][36][37][38][39][40][41][42]. All patients were with regular menstrual cycles of 25-32 days, presumed to be ovulatory.…”

“…However, in women above 35 years of age, poor responders, or with more severe pituitary GnRH-a suppression, stimulation with r-LH in the mid/late-follicular phase could be associated with improved results [6,12,24,34,37,40,41,47]. In a recent meta-analysis study it has been suggested that the supplementation with r-LH in patients of advanced reproductive age stimulated with r-FSH, may improve implantation and clinical pregnancy without affecting metaphase II (Met II) yield [31].…”

Assessing predictors for the success of GnRH antagonist protocol in reproductive women in IVF/ICSI - in fresh cycles

“…However, the role of baseline serum LH in predicting the success of IVF in terms of infertility outcomes remains controversial. Inconsistent results have been found, especially with regard to infertile women aged ≥35 years, regardless of whether they were using rLH supplementation during ovarian stimulation or not (6).…”

The Use of rLH, HMG and hCG in Controlled Ovarian Stimulation for Assisted Reproductive Technologies

“…LH receptors are present in the endometrium during the window of implantation (9, 10), but whether these receptors play a direct role in embryo implantation needs further investigation. An indirect effect on the endometrium has been proposed via decreased premature progesterone secretion (24,45). There is a growing body of evidence to suggest that prematurely elevated progesterone levels on the day of hCG have a negative impact on embryo implantation without affecting embryo quality (46)(47)(48)(49)(50)(51).…”

“…LH stimulates CYP17 in thecal cells to further convert the progesterone to androgens, which are subsequently aromatized in the granulosa cell (3). Under the two-cell two gonadotropin model, LH is protective of premature progesterone elevations prior to luteinization (24,45) (Figure 3). Further investigation is needed to determine if exogenous LH administration is protective for the endometrium.…”